Annexon shares fall 33% after patients drop out of Huntington’s trial; Two Chinese biotechs net modest financing rounds

Annexon has some disappointing news, and it is evident at the Nasdaq.

Annexon, which went public back in 2020, had its share price $ANNX tumble more than 30% down to $7.30 on Wednesday after several patients discontinued treatment...

Click to view original post